Skip to main content

Table 6 Base case results, Sweden

From: Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

  Cost components (EUR)
Treatment costs GP/A&E visits Hospital Triptan treatment Total direct costs
Botox 8535 12,949 1338 472 23,293
Placebo 2749 14,087 1488 522 18,846
  Total and incremental results
Total costs (EUR) Discounted total costs (EUR) Incremental cost (EUR) Total QALYs Discounted QALYs Incremental QALYs ICER
Botox 23,293 20,700 4126 6.505 5.711 0.223 18,506
Placebo 18,846 16,574 6.257 5.488
  1. Key: A&E Accident and emergency; GP General practitioner; ICER Incremental cost-effectiveness ratio; QALY Quality adjusted life years. Note: Treatment costs include the administration cost for Botox and the neurologist visits for both Botox and placebo